Get Premium

Get Premium

Dominate Financial Markets with Stock Target Advisor Premium Features

Discover
Discover

Explore new stock opportunities and market trends for better investment decisions.
- Analyst Ratings & Stock Picks
- Top Picks By AI
- Latest Analyst Ratings
- Analyst Directory
- Worst Stocks
- Sector Ratings & Performance
- Smart Filters
- Best Penny Stocks
- Best Dividend Stocks
- Best Crypto Stocks
- Best Performing Stocks
- Worst Performing Stocks
- Highest Income ETFs
Research
Research

Access in-depth stock analysis and expert evaluations to guide your investments
- Automatic Selection
- Stocks/ETF Screener
- Query Builder
- Analyst Screener
- Automated Research Reports
- Best Stocks Filters
- Thematic Stock Screens
- Sector Stock Screens
Learn
Learn

Utilize our extensive educational resources designed to enhance your investing knowledge and skills
- Market News & Insights
- Stock Target Advisor Insights
- Tutorials
- Market News
- Stock Calendars
- Earnings Calendar
- IPO Calendar
- Splits Calendar
Watchlists & Portfolios
Watchlists & Portfolios

Easily manage, track, and optimize your stock selections for maximum returns
Engage
Engage

Connect with the investing community and access free widgets for better stock insights
Pricing

Guessing Isn’t a Strategy!

Use Research That Shows You What to Buy, When to Buy, and Why—Now Upto 70% OFF! Claim Now

Intellia Therapeutics Inc (NTLA) Financial Statements

COMMON STOCK | Biotechnology | NSD

Target Add to Watchlist

Take a Tour

Buy

Average Analyst
Rating

Bearish

Stock Target Advisor
Analysis

Strong Buy

Average User
Rating

Last Closing Price

USD 7.92

Change

+0.69 (+9.54%)

Market Cap

USD 0.93B

Volume

5.62M

Avg User Target

USD 59.56 (+652.02%)

NTLA

Intellia Therapeutics Inc (USD)

COMMON STOCK | NSD

USD 7.92

+0.69 ( +9.54%)

Watchlist

Intellia Therapeutics Inc (NTLA) Annual Income Statement (USD)

NTLA Quarterly Financials (USD)

Frequently Asked Questions About Intellia Therapeutics Inc (NTLA) Stock

Intellia Therapeutics Inc's (NTLA) last reported annual revenue was USD 57.88 Million.

Intellia Therapeutics Inc's (NTLA) annual revenue growth rate based on the revenue reported in the past 5 years is : 6.07%

Intellia Therapeutics Inc's(NTLA) is not profitable as of its last reported annual financials.

The net profit margin for Intellia Therapeutics Inc's(NTLA) from its laster reported year is -896.77%

The return on equity (ROE) for Intellia Therapeutics Inc's(NTLA) from its last reported annual financials is : -54.01%

The return on assets (ROA) for Intellia Therapeutics Inc's(NTLA) from its last reported annual financials is : -26.80%

The return on invested capital (ROIC) for Intellia Therapeutics Inc's(NTLA) from its last reported annual financials is : -55.59%

The Debt to Equity ratio for Intellia Therapeutics Inc's(NTLA) from its last reported annual financials is : 0.00%

The dividend yield for Intellia Therapeutics Inc's(NTLA) from its laster reported year is 0.00%

Intellia Therapeutics Inc's(NTLA) has negative cash flow as of its last reported annual financials.

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What not to like

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.